Skin toxicities associated with tumor treating fields: case based review

Rimas V. Lukas, Kelley L. Ratermann, Eric T. Wong, John L. Villano*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The novel anti-mitotic based tumor treating fields (TTFields) is FDA approved for recurrent glioblastoma. Recently the phase III upfront trial combining the Novo TTF-100A device, called Optune, with temozolomide following concurrent radiation therapy and chemotherapy, demonstrated improvement in survival. Wider use of this novel therapy is expected. The most common adverse event is dermatologic, which dominates compared to the next most frequently observed adverse event of headaches, the incidence of which was even in both arms in the phase III registration trial for recurrent glioblastoma. Our case review outlines the presentation, treatment, and outcome of representative patients using TTFields. In summary, preventative strategies to inform and educate patients and operators can prevent many of these dermatological events. Skin toxicity in the setting of concurrent use of TTFields with other therapies such as bevacizumab is an unknown and will need to be closely followed.

Original languageEnglish (US)
Pages (from-to)593-599
Number of pages7
JournalJournal of Neuro-Oncology
Issue number3
StatePublished - Dec 1 2017


  • Brain tumor
  • Glioblastoma
  • Infection
  • Skin
  • Tumor treating fields

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Skin toxicities associated with tumor treating fields: case based review'. Together they form a unique fingerprint.

Cite this